Drug Profile
RVx 201
Alternative Names: RVx-201; RVx-201 HSV-2; TheravaxHSV-2Latest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Southern Illinois University School of Medicine; University of Kansas
- Developer Rational Vaccines
- Class Attenuated vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections
Most Recent Events
- 26 Feb 2024 Preclinical trials in Herpes simplex virus type 1 infections (Prevention) in USA (parenteral) prior to February 2024 (Recepta Biopharma pipeline, February 2024)
- 26 Feb 2024 Preclinical trials in Herpes simplex virus type 1 infections in USA (parenteral) prior to February 2024 (Recepta Biopharma pipeline, February 2024)
- 26 Feb 2024 RVx 201 is still in preclinical trials for Herpes simplex virus type 2 infections (Prevention) in USA (Intradermal) (Recepta Biopharma pipeline, February 2024)